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Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4)
in normal and malignant human tissues
Aims: Delta-like ligand 4 (DLL4) is one of five known
Notch ligands in mammals and interacts predomi-
nantly with Notch 1. DLL4 is induced by vascular
endothelial growth factor (VEGF) and acts downstream
of VEGF as a ‘brake’ on VEGF-induced vessel growth,
forming an autoregulatory negative feedback loop
inactivating VEGF. This action was believed to occur
only in vascular development, raising hopes that DLL4
could be a specific drug target for controlling vessel
growth in tumours and other pathological conditions.
Our aim was to pursue this by raising a monoclonal
antibody to the internal domain of DLL4 and assess its
distribution in normal and malignant tissues in com-
parison with antibodies against the external domain of
DLL4.
Methods and results: The anti-DLL4 monoclonal anti-
body was raised using conventional mouse hybridoma
techniques. The antibody has been fully characterized
by Western blotting and transfectant immunostaining.
It has also been comprehensively compared with other
antibodies against both the internal and external
domains of DLL4. The antigen is widely expressed on
human tissues not only on endothelium but also on
epithelium and stromal cells. Indeed, in our compre-
hensive survey only pulmonary alveoli failed to express
DLL4. Of a wide range of malignancies, most also
expressed DLL4 on tumour cells with a predominantly
cytoplasmic pattern, although a number also displayed
nuclear positivity.
Conclusions: Contrary to previous beliefs, DLL4 is
widely distributed in tissues other than vessels includ-
ing many malignancies. Furthermore, the molecule is
internalized on binding its receptor and often trans-
ported to the nucleus. These findings raise many
interesting possibilities for further study of DLL4 and
its potential as a therapeutic target.
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Abbreviations: DAPI, 4¢,6-diamidino-2-phenylindole; DLL4, delta-like ligand 4; ECD, extracellular domain; HUVEC,
human umbilical vein endothelial cells; ICD, intracellular domain; PMA, phorbol myristate acetate; PBS,
phosphate-buffered saline; VEGF, vascular endothelial growth factor
Introduction
The generation of new vessels by tumour cells (neoplas-
tic angiogenesis) is a hallmark of cancer and provides
oxygen and nutrients to allow tumour growth.1 Since
vascular endothelial growth factor (VEGF) is the most
potent inducer of vessel production, anti-angiogenic
therapy has been oriented towards blocking VEGF and
VEGF receptors. This has led to increased patient
survival in some tumour types.2–4 However, some
tumours do not respond to VEGF blockade, and others
that initially respond later become resistant.5–7
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The Notch signalling pathway is a well-known
regulator of embryological development and many
important cellular functions including vascular devel-
opment.8
There are four Notch receptors in mammals (Notch1
to Notch4) and five ligands (Jagged 1 and 2, and delta-
like 1, 2 and 4). Ligand receptor interaction is followed
by two successive proteolytic cleavages of Notch. This
is followed by translocation of the intracellular domain
of the Notch receptor into the nucleus, initiating its
transactivation activity and regulating the expression
of other genes.9
Recent studies have focused on one of the ligands of
the Notch 1 receptor, delta-like ligand 4 (DLL4), which
is induced by VEGF and acts downstream of VEGF as a
‘brake’ on VEGF-induced vessel growth, forming an
autoregulatory negative feedback loop inactivating
VEGF.10–12 Three different experimental systems, retinal
development in the mouse eye, zebrafish embryos and
tumours implanted in mice, have shown that Notch
inhibition is followed by an increase of sprouting and
branching of new vessels in association with gradients of
VEGF protein. In contrast, VEGF blockade by pharma-
cological or genetic inactivation induces reduction of
DLL4 expression and vessel sprouting, indicating that
the Notch pathway acts downstream of VEGF.10–16
It has been shown that DLL4 is a potential drug
target. Administration of a neutralizing DLL4 antibody
or a recombinant DLL4 protein, aimed at blocking the
Notch–DLL4 pathway, delayed tumour growth in
mice.13,14 In keeping with studies on zebrafish embryos
and mouse retina, blockade of DLL4 expression induced
an increase of sprouting and branching of vessels,
leading to an increase of vascular density in tumours.
However, functional studies reveal that these newly
formed vessels were inefficient and not connected to the
vascular network of the tumours, resulting in inhibi-
tion of tumour growth.
DLL4 blockade has been shown to be effective in the
treatment of VEGF-resistant tumours.13,14 Moreover, in
addition to the antitumoral action of DLL4 alone,
combined treatment with anti-VEGF has been shown to
be more efficient in tumour growth control.13
The next step is to address whether these observa-
tions in experimental animal systems can be extra-
polated to human neoplasia. For that aim, a
prerequisite is the development of good antibodies
capable of identifying DLL4 protein expression in
human tissues, especially in routinely fixed and
processed human specimens.
This study was undertaken to generate a monoclonal
antibody against human DLL4 and to characterize its
distribution and expression in normal, reactive and
neoplastic human tissues in order to gain insight into
the biological functions of DLL4 protein in normal,
reactive and neoplastic development.
Materials and methods
production of monoclonal antibody
The D4 ⁄ 37 antihuman monoclonal antibody was
generated against the intracellular domain (ICD) of
human DLL4, by means of a recombinant DLL4 protein
expressed in Escherichia coli, as described previously.17
Monoclonal antibodies were raised using conventional
mouse methods.
other antibodies
The expression and characterization of the D4 ⁄ 37
monoclonal antibody raised against the ICD of DLL4
was performed in in vitro studies and in human tissue
biopsy specimens of different neoplastic and reactive
conditions. This study was combined with parallel
immunocytochemistry with the R3 polyclonal antibody
targeting the DLL4 ICD17 and with one commercially
available polyclonal antibody against the extracellular
domain (ECD) of DLL4 (Ab7280; Abcam, Cambridge,
UK). These two antibodies were used as cross controls
for DLL4 protein expression signal specificity. The anti-
macrophage monoclonal antibody KP1 against CD68
(Dako A ⁄ S, Glostrup, Denmark) was also used.
transfectants
Full-length hDLL4ECD and DLL4ICD were cloned into a
pcDNA3.1 vector and the corresponding expression
vector was transfected into the Chinese hamster ovary
cell line with the Fugene 6 transfection reagent.
cell culture
Human cell lines A549, MDA468, SKBr3, K562,
MCF7, U87 and U937 were prepared under both
normoxic and hypoxic conditions as previously des-
cribed.17,18
The U937 human histiocytic lymphoma cell line was
used to analyse the possible role of phorbol myristate
acetate (PMA) as an inducible agent of DLL4 in
macrophages.
immunofluorescence
Cytospins of cell lines were made using a Shandon
cytocentrifuge (Thermo Fisher Inc., Waltham, MA
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USA). Frozen sections (8 lm) were air dried and fixed
in acetone for 10 min or in buffered formalin for 1 min.
Primary antibody was applied for 1 h for D4 ⁄ 37 and
2 h for Ab780 and washed for 5 min in phosphate-
buffered saline (PBS). Fluorochrome-conjugated sec-
ondary antibodies [antimouse, IgM 488 (green), IgG
568 (red), diluted 1:100, and antirabbit, 568 (red) or
488 (green), diluted 1:100 (Alexa Fluor, Molecular
Probes Inc., Oregon, USA)] were applied for 45 min
and washed for 5 min in PBS. 4¢,6-Diamidino-2-
phenylindole (DAPI) nuclear stain was achieved by
mounting in Dako fluorescent mounting medium,
containing 2 ll DAPI at 1 mg ⁄ ml (DAPI FluoroPureTM
grade; Molecular Probes, Eugene, OR, USA), in 1 ml of
mountant. Slides were left in a cold darkroom over-
night. Observation and image acquisition were per-
formed with a Zeiss LSM510 confocal microscope.
western blot analysis
Western blot analysis was performed as described
previously.19,20
human tissue studies
Material
Biopsy specimens of human tumours were obtained
from the Cellular Pathology Department, John Radcliffe
Hospital (Oxford, UK) and used to construct multitissue
arrays containing colorectal, kidney, lung and breast
cancer, as well as normal tissue specimens. Brain
tumour tissue arrays containing meningiomas, glio-
blastomas and oligodendroglial tumours were retrieved
from the Department of Pathology, Hospital Universi-
tario 12 de Octubre (Madrid, Spain). Formalin-fixed
paraffin-embedded 4-lm tissue sections or tissue array
sections were mounted onto Snowcoat X-tra Micro-
Slides.
Immunohistochemistry
Immunohistochemical reactivity was produced using
the Dako Real EnVision rabbit ⁄ mouse method (Dako
A ⁄ S). Reactive non-neoplastic tissue specimens from
cases of tonsillitis, nephritis and reactive gliosis were
used as a reference for DLL4 protein expression in non-
neoplastic inflammatory ⁄ proliferative lesions. Incuba-
tion with an unrelated antibody was employed as a
control of antigenic preservation and recovery.
In situ hybridization
Radioactive in situ hybridization was performed in
paraffin tissue sections from 20 breast, 20 kidney and
10 bladder cancer specimens, according to the method
developed by Poulsom et al.21 The cRNA probe for
hybridization was a human DLL4 probe of 741 bp
length fragment S35 labelled, located from position
1775 to 2516 bp. A parallel set of consecutive serial
sections was simultaneously hybridized with a b-actin
probe 428 bases long, generated from the original
pHFBA3¢ clone described by Ponte et al.,22 slightly
modified and kindly provided by Professor R. Poulsom.
After 20 days’ exposure, sections were studied under
bright and dark field conditions with an Olympus BX51
Photo-microscope. All images were captured with a
charge-coupled device Olympus DP70 camera. Slides
were examined under the microscope with bright and
dark field illumination to compare tissue morphology
and hybridization signals.
Ethical approval
Ethical approval was obtained in compliance with
current European and British in situ hybridization laws
and regulations for human tissues and tumours.
Results
dll4 transfectant cell experiments
(f igure 1)
Comparison of the antibodies (D4 ⁄ 37, R3 and
Ab7280) showed that D4 ⁄ 37 and R3 stained only
the ICD DLL4 transfectants, mainly in the cytoplasm
but occasionally in the nucleus. The ECD DLL4-GFP
transfectants did not show any staining. Ab7280, in
contrast, did immunostain the ECD DLL4 transfectants
but was negative on the ICD DLL4 transfectants
(Figure 1).
Immunocytochemistry
Cell lines were tested after normal and hypoxic
conditions of culture. In the cell line MCF10A, estab-
lished from normal breast epithelium and expressing
DLL4, immunoreactivity with Ab7280 was seen in
both cytoplasm and nucleus, whereas D4 ⁄ 37 was
located only in the cytoplasm. In MDA468 and SKBr3
breast carcinoma cell lines, the localization of DLL4
(both ICD and ECD) was cytoplasmic in normoxia.
However after 8–10 h of culture under hypoxic con-
ditions, in addition to DLL4 cytoplasmic expression,
nuclear expression was observed as well.
To check the expression of DLL4 on histiocytic cells
we immunostained U937 cells with D4 ⁄ 37 antibody
before and after stimulation with PMA, which is known
to induce histiocytic differentiation in these cells.
Cytoplasmic expression of both DLL4 and the macro-
phage marker CD68 was weak on untreated cells.
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However, it was strongly expressed in the PMA-treated
samples, with expression of CD68 (cytoplasmic) and
DLL4 (cytoplasmic and nuclear) being dramatically
increased.
Immunoreactivity in VEGF-treated human umbilical vein
endothelial cells
Localization of both the ICD and ECD in untreated
human umbilical vein endothelial cells (HUVEC)
showed cytoplasmic DLL4 protein expression with a
rim-like membranous pattern. Occasional mild nuclear
expression was observed with both antibodies. After
VEGF treatment of HUVEC, DLL4 cytoplasmic reactivity
was increased with prominent nuclear expression.
By confocal microscopy, DLL4 ICD reactivity in both
untreated and VEGF-treated HUVEC displayed moder-
ate to intense cytoplasmic immunopositivity. A weak
granular nuclear signal was observed in some cells.
DLL4 ECD immunoreactivity was similar, but with a
more intense granular nuclear positivity.
By double immunofluorescence staining followed by
laser scanning confocal microscopy, colocalization of
DLL4 ECD (Ab7280) and ICD (D4 ⁄ 37) was shown in
the cytoplasm with areas of accentuation at the cell
membrane.
Western blotting
Extracts of U87 DLL4 transfected cells and non-
neoplastic and neoplastic kidney tissues displaying
DLL4 protein expression by immunocytochemistry
showed the presence of a 75–80-kD band, correspond-
ing to DLL4 protein with both D4 ⁄ 37 and Ab7280.
Western blots from U87 cells that were not transfected
with DLL4 were negative.
dll4 express ion in non-neoplastic tissues
(f igure 2)
Comparative analysis of DLL4 protein expression
showed that all antibodies provided a similar pattern.
As D4 ⁄ 37 was the most sensitive, detailed evaluation
of DLL4 expression was undertaken with this antibody.
Parallel immunohistochemistry with Ab7280 and R3
was used regularly as a control of specificity.
Widespread cytoplasmic and occasional nuclear DLL4
protein expression was observed in non-neoplastic
tissue such as epidermal keratinocytes, dermal vessels
and stromal cells in skin overlying breast cancer biopsy
specimens. Reactive lymphoid tissue displayed strong
DLL4 protein expression in germinal centres, high-
endothelial venules and occasional interfollicular cells.
Neurons and reactive astrocytes of cortical areas infil-
trated by neoplastic cells or from non-plastic gliotic scars
also displayed DLL4 protein expression. DLL4 protein
expression was also observed in non-plastic vessels,
renal glomeruli and tubules and in breast lobules.
Inflammatory cells were also shown to display DLL4
cytoplasmic and nuclear protein expression (Table 1).
dll4 protein express ion in human tumours
(f igure 2, table 2)
DLL4 cytoplasmic protein expression by tumoral vessels
was widely observed in all tumour types stained with
A B C D E F
Figure 1. TOP: Western blots from U87 cells. A, U87 cell line with an
empty vector i.e. DLL4 not transfected. B, U87 cell line transfected
with DLL4 showing a band at the appropriate molecular weight
for DLL4 (75–80 kD) – arrow. Western blots from kidney samples.
C & E, Two samples from normal kidney adjacent to tumours in
D & F. D & F, Two samples from kidney tumours. Note the presence of
a band for DLL4 at 75–80 kD in all renal samples (arrow). BOTTOM:
Double immunostaining of HUVEC with antibody D4 ⁄ 37 (anti
DLL4 ICD) in red and antibody Ab7280 (anti DLL4 ECD) in green.
DAPI Nuclear stain (blue). Observe the cytoplasmic and nuclear
DLL4 ECD expression with focal membrane cytoplasmic reinforce-
ment and delineation of the nuclear membrane. There is also DLL4
ICD cytoplasmic staining which is focally stronger on the cytoplasmic
membrane along with a weak granular nuclear signal in some
cells. Cytoplasmic and focal membrane colocalization is seen in
yellow in the main image on the right.
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the D4 ⁄ 37 monoclonal antibody. Reactivity varied
within different tissues from weak to strong, although
in any given specimen it was usually quite uniform. In
general, positivity of vessels in the tumour was more
marked than in surrounding stromal areas or in
normal tissues.
DLL4 expression was also detected in non-endothe-
lial structures. Neoplastic cells from the majority of the
tumours studied displayed cytoplasmic DLL4 expres-
sion of variable intensity, with areas of high expression
versus others that were weakly positive or negative.
Occasional positive nuclei were observed as well. Signal
intensity was similar to that observed in vessels,
varying from weak to strong. In individual samples
there were areas of tumour cells with little or no
expression alternating with those of strong positivity,
whereas in vessels the expression was more uniform
without significant variations in signal intensity.
A B C D
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Figure 2. A, Normal skin – monoclonal D4 ⁄ 37 and B, Normal skin – polyclonal Ab 7280. Note the positive cytoplasmic and nuclear
expression in the basal and middle layer keratinocytes, dermal vessels and perivascular infiltrates. The number of positive cells and the
signal intensity is higher with D4 ⁄ 37. C, Germinal centre cells in a lymph node – monoclonal D4 ⁄ 37. D, Protoplasmic astrocytes in a
gliotic scar – monoclonal D4 ⁄ 37. E, Normal breast lobular cells – monoclonal D4 ⁄ 37. F, Normal breast lobular cells – radioactive in-situ
hybridization (RISH) on a serial section to E, Showing DLL4 mRNA expression. G, Renal clear cell carcinoma H&E, Stroma to the left of
and tumor to the right of the white line. H, Renal clear cell carcinoma serial section to (G) RISH showing DLL4 mRNA expression by
tumor cells (right) and vessels (left-arrows). Stroma to the left of and tumor to the right of the white line. I, Breast cancer-antibody D4 ⁄ 37
shows cytoplasmic DLL4 protein expression on tumor cells. J, Breast cancer-RISH demonstrating mRNA expression in tumor cells. K,
Breast cancer-antibody D4 ⁄ 37 demonstrates DLL4 cytoplasmic and nuclear protein expression by tumoral cells and by vessels within
the tumor (arrow). L, Breast cancer-antibody D4 ⁄ 37 showing cytoplasmic expression of DLL4 protein by neoplastic cells and vessels
(arrows) and nuclear and cytoplasmic expression by inflammatory cells in breast cancer. M, Renal cancer displaying weak cytoplasmic and
strong nuclear DLL4 immunoexpression (antibody D4 ⁄ 37). N, Another renal cancer in which the tumor is negative but the associated
inflammatory cells are positive for the expression of DLL4 (antibody D4 ⁄ 37).
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in s itu hybridization studies
DLL4 mRNA was expressed along intratumoral and
non-tumoral vessels of different sizes in all cases (20
breast, 20 kidney cancer and 10 bladder cancer). At
the cellular level, the distribution of silver grains
clustered over endothelial cells of arterial vessels
outlining the vascular network of neoplastic vessels
as well as vessels of non-tumoral zones, although signal
intensity was more intense in the neoplastic vessels.
Although the vasculature was the most prominent
site of DLL4 expression by in situ hybridization, non-
endothelial DLL4 expression was also observed. Neo-
plastic and inflammatory cells in 15 out of 20 breast,
16 out of 20 kidney and three out of 10 bladder
cancers also displayed DLL4 mRNA expression. Clus-
ters of silver grains lying over neoplastic nuclei and
their surrounding cytoplasm were observed mainly
around necrotic areas and in neoplastic foci infiltrating
fat tissue in breast cancer, although with less intensity
than that observed on vessels.
The pattern of expression was different from that
seen on vascular cells. Instead of the linear distribution
of silver grains observed over endothelial cells in both
neoplastic and inflammatory cells, silver grains aggre-
gated in clusters over the nuclei and surrounding areas
of cytoplasm. Signal intensity varied between tumour
areas from negative or slightly above background to an
increased concentration of more densely packed silver
grain clusters. Sparse accumulations of grains above or
surrounding nuclei of inflammatory cells were fre-
quently shown. DLL4 mRNA expression was also
detected in non-neoplastic breast lobules included in
some of the breast cancer biopsy specimens and in
glomeruli adjacent to kidney cancer specimens as
sparsely distributed clusters of silver grains.
Discussion
In this study, we generated a new monoclonal antibody
against the internal domain of DLL4. The specificity is
supported by in vitro studies of cell lines where D4 ⁄ 37
only stained cells transfected with the internal domain
of DLL4. Western blotting reinforced the specificity of
D4 ⁄ 37, showing that it recognized a 75–80-kD band
corresponding to DLL4 in extracts from transfected U87
cells. Further support comes from immunohistochem-
istry, which showed a similar pattern of reactivity with
all three antibodies, including R3 against another
internal domain antigen and Ab7280 against the
external domain.
Immunohistochemistry of human tissues and
tumours demonstrates that DLL4 protein expression is
not restricted to endothelial cells, but is widespread in
neoplastic as well as reactive tissues. These novel
findings are supported by in situ hybridization studies
that showed a similar distribution in normal and
malignant tissues in endothelial, tumour, inflamma-
tory and reactive cells. Another striking observation
is that nuclear immunoreactivity was also clearly
evident.
Until now the predominant view has been that DLL4
is an endothelial-specific Notch1 ligand that regulates
vascular development. Indeed, DLL4 knockout mice die
intra utero showing developmental vascular malforma-
tions.23 Similar findings have previously been observed
in VEGF knockout mice.24
Table 1. The tissues on the array were scored if they showed
positive (POS) or negative (NEG) staining in certain regions
Tissue Score Remarks
Lymph node POS Germinal centres
Adrenal POS Fasciculata and reticularis
layers
Breast POS Epithelium, vessels
Salivary gland POS Epithelium
Oesophagus POS Ductal epithelium, vessels
Stomach POS Epithelium, vessels, stroma
Pancreas POS Epithelium
Large intestine POS Epithelium
Appendix POS Epithelium, stroma
Liver POS Hepatocytes, biliary ducts
Brain (gliotic scar) POS Astrocytes,
Trachea POS Epithelium, vessels, stroma
Lung NEG Alveoli
Kidney POS Tubules, glomeruli
Cervix POS Stroma, vessels
Endometrium POS Epithelium, vessels, stroma
Ovary POS Stroma
Testis POS Tubules, interstitial cells
Fat POS Vessels
Amnion POS Stroma
Some remarks are added at the side. Every tissue was present
twice or more on the multitissue array slides.
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Other cell types have previously been demonstrated
to express DLL4 mRNA in embryological development.
These include thymic and intestinal epithelium, neural
tube, para-aortic bodies, optic recesses and nerves and
developing retinal and olfactory cells.25 In addition,
DLL4 mRNA expression has been observed on the
neoplastic cells of glioblastomas.18 This suggests that
DLL4 has other roles than solely regulation of vascular
development.
Our study with antibodies D4 ⁄ 37 and Ab7280
against the DLL4 internal and external domain pro-
teins combined with in situ hybridization for DLL4
mRNA has provided the following new findings:
1 DLL4 protein and mRNA expression is not restricted
to endothelial cells. DLL4 expression in reactive
conditions, e.g. neurons and astrocytes in reactive
gliosis or by epithelial cells in nasal mucosa and
skin adjacent to tumours, lymph node germinal
centres or by neurons in areas invaded by neoplas-
tic cells, is consistent with a biological role in
processes other than vascular development and
regulation. This is supported by a recent study
showing that proinflammatory stimuli induce DLL4
protein expression in macrophages leading to
amplification of the inflammatory response.26 Our
results using PMA as an agent to induce DLL4
expression in U937 human histiocytic lymphoma
cells support these findings. Moreover, DLL4 has
been shown to play a role as a regulator of
antiviral immunity.27 Furthermore, oscillating levels
of DLL4 protein expression throughout the men-
strual cycle have been reported in endometrial
glandular cells.28
2 DLL4 protein may be expressed in nuclei, indicating
nuclear translocation after activation and suggesting
that DLL4 may have functional activity there.
Previous studies have shown that after DLL4 and
Notch interact, the extracellular domains are cleaved
and endocytosed by the ligand-expressing cell.29
Endocytosis has long been known as a cellular
mechanism for nutrient capture, signal transduction
and cell membrane composition. Recent studies have
added to this by showing that it can also contribute to
basic cellular organization mechanisms. By means of
RNA interference studies, a high number of kinases
have been shown to play a role in endocytosis,30 which
links it to such cellular activities as cell cycle control,
metabolism and cellular adhesion.31 In the present
context, endocytosis of delta ligands is needed for Notch
activation.32 Studies in flies have shown that delta
ligands are located mainly in cytoplasmic vesicles33
and that endocytosis-defective delta ligands, although
expressed at the cell surface, cannot activate
Notch.34,35 It is known that internalized delta can be
processed by the ubiquitin degradation pathway or
activated and recycled to the plasma membrane, but
nuclear translocation has also been proposed.29
Our finding of DLL4 nuclear expression could be the
result of nuclear translocation. The fact that almost all
previous studies on DLL4 expression have been
addressed by in situ hybridization studies of DLL4
mRNA and not by protein localization may explain
why this finding has not been previously documented.
Findings such as this stress the importance of combined
studies of gene product expression in order to establish
a fuller picture of gene activation and function.
In conclusion, we have generated a robust and well-
characterized monoclonal antibody allowing the study
of the expression and possible function of DLL4 protein
in human tissues that can be used in routine practice.
Future studies are needed to address whether DLL4 has
a role in patient stratification to guide treatment
Table 2. DLL4 protein
expression in different kind
of tumoursCancer Cases
Cytoplasmic expression Nuclear expression
% (+)ve Intensity % (+)ve Intensity
Oligodendroglial 84 81 ⁄ 84 (97%) ++ ⁄ +++ 37 ⁄ 84 (44%) + ⁄ ++
Glioblastomas 20 20 ⁄ 20 (100%) ++ ⁄ +++ 18 ⁄ 20 (90%) + ⁄ ++
Meningiomas 20 20 ⁄ 20 (100%) ++ ⁄ +++ 5 ⁄ 20 (25%) + ⁄ ++
Breast Ca 110 86 ⁄ 110 (78%) ++ ⁄ +++ 23 ⁄ 110 (21%) + ⁄ ++
Kidney 79 76 ⁄ 79 (96%) ++ ⁄ +++ 72 ⁄ 79 (91%) + ⁄ ++
Colorectal 86 59 ⁄ 86 (61%) ++ ⁄ +++ 11 ⁄ 86 (13%) + ⁄ ++
Lung 73 49 ⁄ 73 (67%) ++ ⁄ +++ 14 ⁄ 86 (16%) + ⁄ ++
% (+)ve, percentage of positive cases; signal intensity: (+), mild; (++), moderate; (+++), high.
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decisions that are currently directed towards DLL4 as a
target of anti-angiogenic therapy to stop neoplastic
growth.36–38 The expression in tumour cells should
increase the relevance of these studies, as blocking this
pathway with DLL4 inhibitors would have an impact
not only on the tumour vasculature but also on the
tumour cells themselves.18
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